Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics (NASDAQ: ATRA) is a leading innovator in cellular immunotherapy, developing transformative treatments for cancer and autoimmune diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely updates on T-cell therapy advancements, including CAR T platform developments and collaboration progress with Memorial Sloan Kettering Cancer Center. Our curated collection features press releases about product candidates in oncology and autoimmune research, financial disclosures, and manufacturing updates.
Key content includes analysis of Phase 1-3 trial outcomes, FDA communications regarding allogeneic therapies, and licensing agreements supporting ATRA's pipeline development. Bookmark this page for direct access to primary source materials and objective reporting on the company's progress in addressing unmet medical needs through innovative immunotherapies.
Atara Biotherapeutics (Nasdaq: ATRA) has appointed Dr. Cokey Nguyen as Chief Scientific Officer, enhancing its focus on T-cell immunotherapy. Dr. Nguyen brings extensive experience from leadership roles at Fate Therapeutics and Pfizer, specializing in oncology and cell therapy. His expertise aims to accelerate Atara's pipeline, which includes therapies for EBV-related diseases and multiple sclerosis. Atara's ongoing commitment to innovation is highlighted as they expand their allogeneic EBV T-cell platform, with a goal of providing transformative treatments for patients with unmet medical needs.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 229,931 restricted stock units and 206,167 stock options to newly hired employees, approved by its Compensation Committee under the 2018 Inducement Plan. The grants, dated May 3, 2021, aim to attract talent essential for advancing Atara's allogeneic EBV T-cell platform targeting serious diseases. Restricted stock units vest over four years, while stock options have a ten-year term with an exercise price of $14.05 per share. This decision complies with Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics reported financial results for Q1 2021, highlighting progress in its T-cell immunotherapy programs. The company is advancing the tab-cel® BLA and MAA filings, with ongoing discussions with the FDA and EMA. In Q1 2021, cash reserves totaled $435.2 million, with license revenue of $3.6 million. Net losses were $78.3 million, or $0.86 per share. Increased R&D expenses were noted, driven by higher headcount and program costs. Atara anticipates significant milestones in 2021, including interim data from the ATA188 study and presentation of CAR T data.
Atara Biotherapeutics (Nasdaq: ATRA) will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 4:30 p.m. EDT for analysts and investors to discuss the results and receive a corporate update. Participants can join the conference call via phone or through a live audio webcast available on Atara's website. The company is focused on developing T-cell immunotherapies for serious diseases, including solid tumors and hematologic cancers, utilizing its EBV T-cell platform.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 52,019 restricted stock units and stock options for 82,342 shares to newly hired employees. This decision, approved by the Compensation Committee, is part of Atara's 2018 Inducement Plan. The restricted stock units vest over four years, while the stock options have a ten-year term with an exercise price of $14.91 per share, based on the closing price on April 1, 2021. This move aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for new hires.
Atara Biotherapeutics (ATRA) announced positive long-term overall survival (OS) data for tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation. The analysis covered 50 patients from three studies, showing a 62% objective response rate and an 86% two-year survival rate. Atara plans to file a Biologics License Application (BLA) in Q3 2021 and a Marketing Authorization Application (MAA) in Europe in Q4 2021.
Atara Biotherapeutics (Nasdaq: ATRA) announced that its CEO Pascal Touchon and CMO AJ Joshi will participate in a fireside chat at the Virtual 33rd Annual ROTH Conference on March 16, 2021, at 4:30 p.m. EDT. The event highlights Atara's commitment to advancing T-cell immunotherapy for serious diseases like solid tumors and autoimmune disorders. A live webcast will be available on the company’s website, with an archived replay for 30 days after the event. Atara is developing therapies leveraging its allogeneic EBV T-cell platform, aiming to address high unmet medical needs.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced the grant of restricted stock units and stock options to new employees as part of its 2018 Inducement Plan. A total of 40,800 restricted stock units and 55,000 stock options will be distributed, vesting over four years contingent on continued employment. The stock options have a ten-year term with an exercise price set at $17.10 per share, the closing price on March 1, 2021. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) to incentivize new talent.
Atara Biotherapeutics (Nasdaq: ATRA) reported its financial results for Q4 and full year 2020, highlighting key business milestones and future catalysts. The company anticipates a rolling BLA filing for tab-cel® in Q3 2021 and plans to submit an EU MAA for EBV+ PTLD in Q4 2021. With cash totaling $500.7 million as of December 31, 2020, Atara believes it can fund operations into 2023. However, the company reported net losses of $81.3 million for Q4 2020, compared to $78.5 million in Q4 2019, and R&D expenses increased to $244.7 million for the full year.
Atara Biotherapeutics (Nasdaq:ATRA) plans to release its fourth quarter and full year 2020 financial results on March 1, 2021, post market close. The company will host a conference call and webcast at 4:30 p.m. EST to discuss the results and provide a corporate update. Analyst participation is encouraged, with call-in options available for domestic and international callers. Atara focuses on T-cell immunotherapy, particularly in treating serious diseases like solid tumors and hematologic cancers using its allogeneic EBV T-cell platform.
